A new trading day began on Tuesday, with Verrica Pharmaceuticals Inc (NASDAQ: VRCA) stock price down -44.23% from the previous day of trading, before settling in for the closing price of $1.43. VRCA’s price has ranged from $1.04 to $11.41 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -13.60%. Meanwhile, its annual earnings per share averaged -1.39%. With a float of $26.07 million, this company’s outstanding shares have now reached $42.41 million.
Let’s determine the extent of company efficiency that accounts for 100 employees. In terms of profitability, gross margin is 84.14%, operating margin of -563.14%, and the pretax margin is -625.06%.
Verrica Pharmaceuticals Inc (VRCA) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Verrica Pharmaceuticals Inc is 38.89%, while institutional ownership is 43.59%. The most recent insider transaction that took place on Aug 26 ’24, was worth 69,647. In this transaction CHIEF LEGAL OFFICER of this company sold 26,183 shares at a rate of $2.66, taking the stock ownership to the 115,303 shares. Before that another transaction happened on Aug 27 ’24, when Company’s CHIEF LEGAL OFFICER sold 9,530 for $2.46, making the entire transaction worth $23,444. This insider now owns 105,773 shares in total.
Verrica Pharmaceuticals Inc (VRCA) Recent Fiscal highlights
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.53 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.39% per share during the next fiscal year.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Trading Performance Indicators
Here are Verrica Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.83, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -0.85 in one year’s time.
Technical Analysis of Verrica Pharmaceuticals Inc (VRCA)
Looking closely at Verrica Pharmaceuticals Inc (NASDAQ: VRCA), its last 5-days average volume was 1.04 million, which is a jump from its year-to-date volume of 0.45 million. As of the previous 9 days, the stock’s Stochastic %D was 17.46%. Additionally, its Average True Range was 0.20.
During the past 100 days, Verrica Pharmaceuticals Inc’s (VRCA) raw stochastic average was set at 0.61%, which indicates a significant decrease from 5.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 253.11% in the past 14 days, which was higher than the 154.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6766, while its 200-day Moving Average is $5.2971. However, in the short run, Verrica Pharmaceuticals Inc’s stock first resistance to watch stands at $0.9100. Second resistance stands at $1.0200. The third major resistance level sits at $1.1000. If the price goes on to break the first support level at $0.7200, it is likely to go to the next support level at $0.6400. Now, if the price goes above the second support level, the third support stands at $0.5300.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Key Stats
With a market capitalization of 34.03 million, the company has a total of 42,669K Shares Outstanding. Currently, annual sales are 5,120 K while annual income is -67,000 K. The company’s previous quarter sales were 5,180 K while its latest quarter income was -17,190 K.
